Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Viral infections

Unclear if antiretrovirals help against COVID-19, initial assessment concludes

A trial published in the Journal of the International AIDS Society has shown that the combined antiretroviral lopinavir/ritonavir has no benefit on clinical outcomes in coronavirus cases.

Open access article

The Royal Pharmaceutical Society has made this article free to access in order to help healthcare professionals stay informed about an issue of national importance.

To learn more about coronavirus, please visit: https://www.rpharms.com/resources/pharmacy-guides/wuhan-novel-coronavirus

Kaletra lopanivir/ritonavir

Source: DR P. MARAZZI / SCIENCE PHOTO LIBRARY

Researchers from the World Health Organization examined 20 observational studies of the effects of antiretroviral medicines, such as lopinavir/ritonavir, on the clinical outcomes of several respiratory diseases

There is insufficient evidence in the literature to indicate whether antiretroviral medicines, such as lopinavir/ritonavir (LPV/r), are effective in treating or preventing coronavirus disease infections, the authors of a systematic review published in the Journal of the International AIDS Society (26 March 2020) have concluded[1].

The team, made up of researchers from the World Health Organization, identified 20 observational studies that reported the effects of antiretroviral medicines on clinical outcomes in severe acute respiratory syndrome (SARS; n=3), Middle East respiratory syndrome (MERS; n=6), and COVID-19 (n=11), along with one randomised trial in COVID-19.

The randomised trial showed no clinical benefit of LPV/r on clinical outcomes. Across the remaining studies, the evidence was inconclusive and the certainty of evidence for outcomes was low.

LPV/r was suggested for potential use in COVID-19 in rapid guidance from Wuhan University, China, based on previous experience against SARS and MERS. However, the researchers noted it was important that antiretroviral drugs were not directed away from people with HIV.

Several randomised trials are planned to assess the safety and efficacy of antiretroviral medicines for the treatment of coronaviruses.

“While the conduct of such trials is challenging, high-quality evidence is needed to improve clinical and programmatic decisions to use antiretroviral drugs for current and future coronavirus outbreaks,” the researchers concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207891

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.